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Abstract
Introduction: Due to side effects of medications used for chronic pain, combination 
therapy seems to be an appropriate solution for alleviation of chronic pain and reduc-
ing the side effects. The role of inhibitory GABA system is well proven in reducing 
neuropathic pain. Also, special attention has been focused on endogenous morphine 
(endomorphins) in reducing chronic pain originates from damage to the nervous sys-
tem. The purpose of this study is to investigate the analgesic effect of simultaneous 
administration of GABA agonist and endomorphin-1 on neuropathic pain in rat model 
of	spinal	cord	injury	(SCI).	The	role	of	oxidative	stress,	NR1	subunits	of	NMDA	recep-
tors, and α2 subunits of GABA receptors in the spinal cord has also been investigated.
Methods: Spinal cord at level of T6–T8 was compressed. Three weeks after spinal 
cord injury, muscimol and endomorphin-1 were injected (intrathecally once a day for 
7 days) individually or in combination. Mechanical and cold allodynia, thermal and 
mechanical hyperalgesia were evaluated before injection and 15 and 60 min after 
injection. At the end of behavioral experiments, histological and biochemical evalua-
tions were done on prepared spinal cord samples.
Results: Isobologram results showed that combination therapy significantly increased 
the pain threshold comparing to injection of endomorphin-1 (EM) or muscimol alone. 
Histological studies indicated the increased expression of α2 subunits of GABA re-
ceptors,	and	NR1	subunits	of	NMDA	receptors	in	the	spinal	cord.	The	combination	
therapy also increased the glutathione (GSH) and superoxide dismutase (SOD) level 
and decreased the malondialdehyde (MDA) levels in the spinal cord.
Conclusion: Simultaneous administration of muscimol and endomorphine-1 could be 
a new candidate for alleviation of pain resulting from spinal cord injury.
K E Y W O R D S
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1  | INTRODUC TION
Neuropathic	pain	which	is	caused	by	nerve	irritation,	damage,	or	de-
struction of the nervous system, is one of the six classes of chronic 
pain	(Nasiri	Nejad	&	Manaheji,	2003;	NasiriNezhad	&	Sagen,	2005),	
and	characterized	by	an	abnormal	sensation	called	dysesthesia,	ex-
aggerated pain sensation (hyperalgesia), and pain produced by nor-
mally	nonpainful	stimuli	(allodynia)	(Gajavelli,	Castellanos,	Furmanski,	
Schiller,	&	Sagen,	2008;	Hama,	Basler,	&	Sagen,	2006).	Mechanism	
of neuropathic pain is not well understood but it seems that periph-
eral or central mechanism (e.g., increased activity of the excitatory 
pathways or decreased activity of inhibitory pathways) is involved.
GABA is a major inhibitory neurotransmitter that regulates the 
excitability of neurons in the mammalian central nervous system 
(CNS).	 Following	 SCI,	 the	 concentration	 and	 efficacy	 of	 this	 neu-
rotransmitter reduce and lead to the address of an intensified pain 
signaling	to	higher	areas	(Gwak	&	Hulsebosch,	2011;	Yowtak	et	al.,	
2013). GABA has three different receptors: GABA A and GABA C 
receptors are ionotropic and open the chloride ion channels; fast ex-
citatory postsynaptic potentials are blocked by the agonist of these 
GABA receptors. GABA B receptor is metabotropic type and cou-
pled to G-proteins. This receptor reduces calcium inflow or potas-
sium outflow across the cell via the second messenger or reducing 
the level of intracellular CAMP; slow excitatory postsynaptic poten-
tials blocked by agonists of this GABA receptor (Watanabe et al., 
2002). Muscimol is a GABA A receptor agonist and a local anesthetic 
extracted	from	“Amanita	muscaria”	mushroom.	(Johnston,	2014).
The endomorphins are a group of endogenous opioid peptides 
consist of endomorphin-1 and endomorphin-2. They are produced in 
the brain, spinal cord, and possibly other tissues (Hollt, 1986; Zöllner 
&	 Stein,	 2006).	 This	 opioids	 block	 pain	 transmission	 in	 the	 spinal	
cord	through	pre-	and	postsynaptic	mechanisms	(Chen	&	Pan,	2006).	
Moreover, they reduce pain by increasing the activity of inhibitory 
GABAergic interneurons and inhibit the perception of pain in the so-
matosensory	cortex	(Granmo,	Jensen,	&	Schouenborg,	2013).
Central	 sensitization	 is	 another	 neuropathic	 pain	 mechanism,	
and several factors are involved in the creation of this phenomenon. 
Glutamate is a major excitatory neurotransmitter in the nervous sys-
tem	and	contributes	to	75%	of	CNS	stimulations.	NMDA	receptors	of	
Glutamate are inotropic and have high permeability to calcium and so-
dium ions. These receptors play a key role in creating and promoting of 
central	sensitization	(D'Angelo	et	al.,	2013;	Manresa	et	al.,	2014).	In	this	
pathway,	the	activity	of	NMDA	receptors	has	been	greatly	increased,	
resulting in more sodium and calcium influx followed by increasing ex-
citability of neurons (Granmo et al., 2013; Willis, 1985). This pathway 
is inhibited by GABAergic neurons; therefore, reducing the activity of 




will lead to cell death (Xu et al., 2012).
Many studies indicate that free radicals are involved in the devel-
opment of neurodegenerative diseases (Jiang, Akopian, Ho, Walsh, 
&	Andersen,	2000;	Tang	&	Aizenman,	1993;	Yowtak	et	al.,	2013).	In	
addition, reactive oxygen species (ROS) are involved in reducing ex-
citability	and	degeneration	of	GABA-secreting	neurons	(Yowtak	et	al.,	
2013). This coincides with a reduction in the number of inhibitory neu-
rotransmitters that are involved in hyperalgesia after neuronal dam-
age. Any process that disturbs the balance between the production 
and destruction of free radicals can cause irreparable damage to the 
nervous system. Glutathione and superoxide dismutase are the most 
important endogenous antioxidants that play a key role in creating and 
maintaining the redox balance in the central nervous system. Cellular 
redox balance is essential for many internal processes including regu-
lation	of	NMDA	receptor	activity.	So,	 reducing	agents	 increases	the	
activity	of	 this	 receptor,	while	oxidizing	 agents	will	 decrease	 its	 ac-
tivity	(Bodhinathan,	Kumar,	&	Foster,	2010;	Tang	&	Aizenman,	1993).
Some medications are currently used to reduce chronic pain 
caused by SCI, but long-term use of these drugs has many side ef-
fects, and the majority of sufferers do not usually response efficiently 
to routine therapeutic prescriptions (Mehta et al., 2012; Siegan, 
Hama,	&	Sagen,	1997).	Sometimes	combination	of	two	or	more	drugs	
can lower dosage and negative side effects. Moreover, since patients 
with chronic pain have numerous symptoms, use of multiple drugs 
with different therapeutic function can improve different clinical 
manifestations	 (Mao	&	Gold,	2011).	Combination	 therapy	 is	a	new	
and growing approach to the treatment of chronic pain and can be 
more effective than taking a medication individually. In the present 
study, we evaluated the therapeutic effects of endomorphin-1 and 
muscimol on neuropathic pain threshold in a rat model of SCI.
2  | MATERIAL S AND METHODS
2.1 | Animals
In	 this	 study,	male	Sprague–Dawley	 rats	 (140–160	g)	were	housed	 in	
plastic cages at a room with controlled temperature (23 ± 2°C) and 
humidity (50 ± 10%), maintained on a 12-hr light–dark cycle with ad li-
bitum access to food and water. All procedures were approved by the 
institutional animal ethics committee. Animals were randomly divided 
into 7 groups (n = 8): intact animals (control), sham-operated (sham), ani-
mals with spinal cord injury (SCI), SCI animals treated with normal saline 
(SCI + vehicle), SCI animals treated with endomorphin-1 (SCI + EM), SCI 
animals treated with muscimol (SCI + muscimol), and SCI animals treated 
with a combination of muscimol and endomorphin-1 (SCI + combination).
2.2 | Induction of neuropathic pain
Neuropathic	 pain	was	 induced	 by	 compression	 of	 the	 spinal	 cord	
under general anesthesia with an intraperitoneal injection of keta-
mine	 (80	mg/kg)	and	xylazine	 (10	mg/kg).	The	skin	 in	 the	thoracic	
vertebral column area was clean-shaven and scrubbed with povi-
done–iodine. The spinal cord was exposed through an incision on the 
midline, and laminectomy at T6–T8 segments of the spinal cord was 
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performed. The spinal cord is clamped by a micro clamp for 1 min. 
Then, wound was sutured and topical antibiotic was sprinkled. After 
full recovery from anesthesia, animals were kept in group cages for 
a 21-day recovery. Because of urinary retention after SCI, bladder 
massage was done twice a day.
2.3 | Drug treatment
Three weeks after SCI, a PE-10 cannula was inserted into the suba-
rachnoid space through L5-L6 segments of the vertebral column 
under	general	anesthesia	with	a	mixture	of	ketamine	and	xylazine.	
Muscimol and endomorphin-1 (Sigma-Aldrich), as well as normal 
saline, were injected with a Hamilton syringe in respective groups, 
three days after cannula fixation. The optimal dose of muscimol 
(0.01 µg/10 μl) and endomorphin-1 (2/5 µg/10 μl) was administered 
for consecutive 7 days according to our pilot studies. Complete be-
havioral surveys were conducted to determination optimum dose 
of muscimol between 0.01, 0.1, and 1 µg also between doses of 2.5, 
1, and 2 µg of endomorphine (Dose–response studies).
2.4 | Behavioral studies
Mechanical and cold allodynia, as well as mechanical and thermal 
hyperalgesia, were evaluated before, 15 and 60 min after the last 
injection. Basso, Beat-tie, and Bresnahan (BBB) scoring was used to 
assess the motor function of rats. Based on similar studies, we de-
cided to choose between 15, 60, and 180 min to determine the most 
appropriate time for drug efficacy. In fact, in order to get the best ef-
fectiveness time, we selected the minimum effective time after the 
injection (15 min) based on studies and then determined how long it 
would be effective after the injection.
2.5 | BBB
Postinjury locomotor capacity was assessed via the BBB locomotor 
scale method. The BBB score is used for function recovery and lo-
comotor testing in chronic SCI study. The scale (0–21) represents 
sequential	recovery	stages	and	categorizes	combinations	of	rat	joint	
movement, hind limb movements, stepping, forelimb, and hind limb 
coordination, trunk position and stability, paw placement, and tail 
position. Each rat was placed in a clear box and stimulated to move. 
Their movement was controlled with 2 evaluators. Each evaluator 
made a determination of the locomotor capacity of the rats using the 
BBB functional scale.
2.6 | Von Frey
To	 measure	 the	 mechanical	 allodynia,	 Von	 Frey	 monofilaments	
were	used.	The	apparatus	consists	of	an	elevated	horizontal	wire	
mesh stand with a Plexiglas box set on top of the wire grid. The 
box was covered with perforated lids. Opaque separators were 
used to diminish interactions between rats. Animals were habit-
uated for 15 min in the box; then, 6 calibrated nylon filaments 
(diameters	of	4.08,	4.31,	4.56,	4.74,	4.93,	5.18	mm)	were	perpen-
dicularly applied to the plantar surface of the rat hind paws. Each 
application was repeated 5 times for each filament to determine 
the mechanical threshold. The pressure increased gradually and 
linearly until a clear withdrawal of the paw was observed. The 
evaluation was stopped in the case of three positive responses, 
but if no response was elicited, the next higher filament was 
applied.
2.7 | Acetone test
The rats were placed in a transparent plastic cage with a wire mesh 
floor for 20 min. Then, for assessment of cold allodynia, a drop of 
acetone squirted onto the midplantar surface of the hind paw. Brisk 
withdrawal, licking or biting of the hind paw was defined as a posi-
tive response. The test repeated 5 times with an interval of 5 min 
for each paw.
2.8 | Randall–Selitto paw-pressure test
To assess mechanical hyperalgesia, increasing pressure was grad-
ually applied to the right hind paw using analgesia meter (Ugo 
Basile). At this test, with pressing a pedal switch the force is ap-
plied to the animal paw, which is placed on a small plinth under a 
cone-shaped pusher with a rounded tip, which does not hurt the 
animal. When the rat struggled, the pedal was released and read 
off the force scale at which the animal felt pain. Additional weights 




After behavioral tests, histological studies were made on some spi-
nal cord samples for confirmation of spinal cord injury. The rats were 
deeply	anesthetized	with	ketamine	and	xylazine.	Transcardially	per-
fusion of 0.2 M phosphate buffer saline (PBS) and aldehyde solution 
containing	4%	paraformaldehyde	and	0.2%	glutaraldehyde	in	0.2	M	
PBS	 (pH	=	7.4)	was	made	to	fix	 the	spinal	cord	tissues.	Then,	by	a	
dorsal incision over the thoracic region and laminectomy, the spinal 
cord was exposed and the T6–T8 segments were removed accord-
ing to the rat anatomical landmarks and kept in plastic containers 
filled	with	4%	paraformaldehyde	at	ambient	temperature	for	24	hr.	
For	 cryoprotection,	 the	 segments	were	 immersed	 in	 25%	 sucrose	
solution. By using cryostat microtome, 20-µm tissue sections were 
prepared and air-dried for 5 hr. They were dewaxed and stained 
4 of 11  |     HOSSEINI Et al.








200 μl ice-cold lysis buffer (RIPA Lysis Buffer) with an electric homog-
enizer,	rinsed	the	blade	twice	with	another	200	μl lysis buffer, and 
then centrifuged at 13,000 × g	at	4°C	for	20	min.	Supernatants	were	
taken	and	stored	at	−80°C	until	Western	blotting.	To	investigate	pro-
tein expression, 2.5 μl of lysate was removed to perform a protein 
quantification assay, and using a plate reader, the protein concentra-
tion of 150 μg was determined for each cell lysate. Changes in pro-
tein expression of α2	subunit	of	GABA	A	receptor	[(abcam,	ab72445),	
Concentration used:1/1000], secondary antibody [(abcam, ab97200 
Concentration	used:	1/5000]	and	NR1	subunit	of	NMDA	receptor	
[(abcam, ab52177), Concentration used:1/1000], and secondary an-
tibody [(abcam, ab ab205718 Concentration used: 1/50000] were 
assessed with Western blotting, according to blotting protocol.
The selected housekeeping gene was β-actin, and antibeta-actin 
antibody (ab8227) was used to detect it. We used TotalLab V1.11 soft-
ware	to	analyze	the	data.	Relative	intensities	of	the	bands	of	interest	
were	 analyzed	with	 TotalLab	 V1.11	 software	 (Nonlinear	Dynamics).	
The gene expression level (α2	 subunit	of	GABA	A	and	NR1	subunit	
of	NMDA)	was	determined	semiquantitatively	by	calculating	the	ratio	
from the target gene in relation to internal standard (β-Actin).
2.12 | Evaluation of oxidative stress
To	evaluate	levels	of	SOD,	GSH,	and	MDA,	tissue	preparation,	4	ani-
mals from each group, and extraction of protein were performed as 
described earlier for Western blot.
2.13 | Measurement of superoxide dismutase
Superoxide anion converts to hydrogen peroxide and oxygen by super-
oxide dismutase. The SOD activity was measured by the Worthington 
method.	0.1	M	EDTA	in	0.3	mM	of	sodium	cyanide	and	1.5	mM	NBT	
added to sample in a Covet and vortexed for 5 min at 37°C. Then, 
0.12 mM riboflavin in 0.067 M potassium phosphate buffer (pH = 7/8) 
was added and placed at room temperature for 10 min. Absorption at a 
wavelength of 560 nm was read within 5 min, and specific activity was 
calculated based on units of milligram protein.
2.14 | Measurement of glutathione
Glutathione is an antioxidant that protects cell components from 
ROS,	 such	 as	 free	 radicals	 and	 peroxides.	 The	Dietz	method	was	
used to determine tissue GSH level. The samples were mixed with 
5% sulfosalicylic acid and centrifuged at 2000 g	at	4°C	for	10	min.	
A total of 100 µl of the supernatant was added to 810 µl of 0.3 M 
disodium phosphate. The reaction was started with adding 90 µl of 
0.04%	DTNB	reagent	in	0.1%	sodium	citrate.	Absorbance	amount	at	
412	nm	was	read	within	5	min.	Using	1	mg/µl	GSH	solution,	stand-
ard curve plotted and the concentration of GSH in the samples was 
calculated.
2.15 | Measurement of malondialdehyde
Malondialdehyde (MDA) level as a lipid peroxidation index is used to 
indicate the extent of damage caused by ROS. MDA reacts with thio-
barbituric acid, and red color is absorbed in wavelength of 532 nm. 
To measure MDA, 250 µl of samples was added to 10 µl of buty-
lated hydroxytoluene-1; then, 250 µl of 1 M phosphoric acid and 
250 µl of thiobarbituric acid were added to microtubes. The samples 
were vortexed and incubated at 60°C for 60 min. In the next step, 
the samples were centrifuged in 10, 000 g for 2–3 min and absorb-
ance was read at a wavelength of 532 nm with a spectrophotometer. 
The standard curve was created based on various concentrations of 
tetramethoxypropane, and the optical density of the samples was 
adapted on the standard curve.
2.16 | Statistical analysis
All results were shown as means ± SEM.	The	results	were	analyzed	
for	statistical	significance	by	one-way	ANOVA	test	and	Tukey's	post	
hoc	multi-comparison.	A	two-way	ANOVA	test	and	Bonferroni	post	
hoc were applied for the time course (comparison of before vs. after 
treatment).	Repeated	measures	ANOVA	was	carried	out	to	change	
the pain over time among before, 15, 60, and 180 min after treat-
ment to clear the time of peak effect. In all calculations, p-value < .05 
was taken as significant.
3  | RESULTS
3.1 | Locomotor function after spinal cord injury
As	shown	in	(Figure	1),	compression	of	spinal	cord	led	to	the	creation	
of a cavity in the spinal cord. Locomotor function was assessed after 
SCI	for	4	min	using	the	BBB	locomotor	rating	scale.
The average of this test for SCI group in the first week was 5.313, 
second week 8.688, third week 10.073, and fourth week 11.135. 
According to the BBB scale, locomotor function in SCI group signifi-
cantly decreased p	<	.001	(Figure	2).
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3.2 | Pain threshold after combination therapy
The	analgesic	effect	of	7	days'	intrathecal	administration	of	mus-
cimol and endomorphin-1 individually and in combination was as-
sessed 15 and 60 min after the last injection in the 7th day, in 
respective groups. Cold (df: 21,2; F = 6.13; p < .05) and mechani-
cal (in 15 min, df: 21,2; F = 18.5; p < .001), (in 60 min, df: 21,2; 
F = 7.2; p	=	.004)	allodynia	evaluation,	showed	that	pain	threshold	
at 15 min after the last injection in the SCI group that received 
a combination of drugs has significantly increased in comparison 
with other groups. In addition, this effect was remained 60 min 
after the last injection. Pain threshold changes in mechanical hy-
peralgesia (in 15 min, df: 21,2; F = 6.63; p = .006), (in 60 min, df: 
21,2; F = 6.63; p < .05) assessment represented the same results 
(p	<	.001;	Figure	3).
3.3 | GABA A receptor's α2 subunit expression after 
combination therapy
As	indicated	in	(Figure	4),	SCI	has	significantly	reduced	the	amount	
of GABA A receptor expression compared to control and Sham group 
(p < .001). Administration of muscimol, in SCI + muscimol group, did 
not have a significant effect on increasing α2 subunit expression, but 
as	shown	in	(Figure	4),	the	level	of	α2 subunit expression significantly 
F I G U R E  1   T6–T8 segments of the 
spinal cord. Compression of the spinal 
cord led to the creation of a cavity in the 










F I G U R E  2   BBB scale, locomotor function significantly 
decreased	after	SCI.	Normal:	before	SCI.	*p	<	.001.	First	week	was	
5.313, Second week 8.688, third week 10.073, and fourth week 
11.135
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increased in SCI + EM and combination therapy groups compared to 
SCI group (p < .001).




on the other hand, it was found that the prescription of drugs did not 
reduce	the	level	of	expression	of	NR1	subunit	in	respective	groups.	
This is while muscimol could reduce the level of expression of this 
subunit significantly compared the SCI group (p	<	.001;	Figure	5).
3.5 | Effect of combination therapy on 
oxidative stress
In this study, effects of combination therapy on the spinal cord, GSH 
and SOD activities, as well as MDA level, were assessed. Our re-
sults showed a significant increase in MDA level in the SCI group 
as compared with the control and sham group. This increase was 
F I G U R E  3  Effect	of	7	days'	intrathecal	administration	of	muscimol,	Endomorphin-1,	and	the	combination	of	these	two	drugs	on	
symptoms	of	neuropathic	pain.	(a)	Cold	allodynia	(Acetone	test),	(b)	mechanical	allodynia	(Von	Frey	test),	and	(c)	mechanical	hyperalgesia	
(Randall–Selitto paw-pressure test). Data presented as mean ± SEM. Pain threshold 15 and 60 min after Combination therapy significantly 
increased.	Administration	of	vehicle	(saline)	was	no	different	from	pretreatment	(data	not	shown).	*p	<	.05,	**p	<	.01,	***p < .001 significant 
difference between SCI + combination group with SCI + muscimol and SCI + EM groups. #Significant difference at p < .001 level with same 








Mean 100.0000 30.0000 67.5000








Mean 95.0000 52.5000 87.5000








Mean 98.7500 61.2500 87.5000
SEM 1.25000 7.42522 4.11877
(a) (b)
(c)
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attenuated by treatment with muscimol and endomorphin-1 in com-
bination (p	<	.05;	Figure	6).	When	compared	with	the	sham	and	con-
trol	group,	the	activities	of	antioxidant	enzymes	GSH	and	SOD	were	
significantly decreased in SCI animals. Treatment with muscimol and 
endomorphin-1 in combination and individually markedly increased 
GSH and SOD activity when compared with the SCI group (p < .05; 
Figures	7	and	8).
4  | DISCUSSION
Neuropathic	 pain	 occurs	 after	 primitive	 damage	 or	 impairment	 of	
neuronal function, in the peripheral or central nervous system. In 
recent years, in order to investigate the mechanisms of this type 
of pain and the effect of different therapeutic agents on it, several 
animal models have been proposed, in which the SCI model is more 
acceptable for its similarity to clinical manifestations of the disease 
in human. One of the methods used by the researchers in the last 
decade	is	the	use	of	vascular	micro	clamping	(Kerimoğlu	et	al.,	2007).	
The advantage of this method is that the risk of infection after the 
lesion is low, resulting in a reduction in the mortality rate due to the 
possibility of better care and also the specificity and precision of the 
lesion	site	(Liang	&	Gross,	1999).
Today, drugs that are commonly used to relieve pain have un-
wanted side effects, especially in the pain-tolerant dose and the com-
bination of these drugs can reduce the administered dose (Attal et al., 
2010;	Mao	&	Gold,	2011).	In	the	present	study,	the	effect	of	combi-
nation therapy with intrathecal administration of muscimol and endo-
morphin-1 as a GABA and μ-receptor agonist was investigated in a rat 
model of SCI.
The symptoms and signaling pathways of neuropathic pain are 
multiple and complex. The most important symptoms are abnormal 
F I G U R E  4  GABA	A	receptor's	α2 
subunit expression in Western blot. 
*Significant	difference	at	p < .001 
in comparison with control group. 
#Significant difference at p < .001 in 
comparison with the SCI group. Control: 
205.3,	Sham:	185.1,	SCI:	133.864,	
SCI	+	Vehicle:	145.146,	SCI	+	EM:	
168.059, SCI + Muscimol: 139.018, 
SCI + Combination: 199.308
F I G U R E  5  NMDA	receptor's	NR1	
subunit expression in Western blot. 
*Significant	difference	with	the	control	
group at p < .05; #Significant difference 
with SCI group at p < .05. $Significant 
difference between the combination 
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responses to stimuli, such as allodynia and hyperalgesia, which can be 
evaluated by behavioral tests. Therefore, analgesic drugs affecting 
this type of pain are more likely to be pharmacologically evaluated 
based on changes in the rate and quality of these two characteris-
tics	(allodynia	and	hyperalgesia)	(Nakamura,	Tajima,	Kawagoe,	Kanai,	
&	Mitsuhata,	2009;	Yowtak	et	al.,	2013).	In	this	study,	it	was	found	
that a once-injected combination of muscimol and endomorphin-1, 
at 15 min after injection, produced a statistically significant reduc-
tion	 in	cold	allodynia	 (as	demonstrated	 in	Figure	3),	but	 it	was	not	
significant compared with administration of each drug individually. 
However, using a combination of drugs for seven consecutive days 
led to significant changes in animal pain threshold in comparison with 
F I G U R E  6  Effect	of	7	days'	intrathecal	administration	of	muscimol,	Endomorphin-1,	and	the	combination	of	these	two	drugs	on	level	
of	MDA	in	the	spinal	cord	tissue.	*Significant	difference	at	p < .05 with the control group; #Significant difference at p < .05 with SCI. 
Data presented as mean ± SEM.	Control:	6.466,	Sham:	5.436,	SCI:	15,	SCI	+	Vehicle:	13.88,	SCI	+	EM:	9.793,	SCI	+	Muscimol:	12.290,	
SCI + Combination: 7.703
F I G U R E  7  Effect	of	7	days'	intrathecal	administration	of	muscimol,	Endomorphin-1,	and	the	combination	of	these	two	drugs	on	level	of	
SOD	in	the	spinal	cord	tissue.	*Significant	difference	at	p	<	.05	with	the	control	group,	**Significant	difference	at	p < .01 with the control 
group, and #significant difference at p < .05 with SCI group. Data presented as mean ± SEM. Control: 15.866, Sham: 16.530, SCI: 5.663, 
SCI + Vehicle: 5.966, SCI + EM: 9.130, SCI + Muscimol: 8.380, SCI + Combination: 12.090
F I G U R E  8   Changes in the level of 
GSH	in	the	spinal	cord	tissue.*Significant	
difference at the p < .05 with the 
control group; #significant difference 
at p < .05 with SCI. Data presented 
as mean ± SEM. Control: 19.66, Sham: 
16.936,	SCI:	7.34,	SCI	+	Vehicle:	7.296,	
SCI + EM: 11.176, SCI + Muscimol: 10.613, 
SCI + Combination: 15.773
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the administration of drugs individually. Behavioral studies showed 
that a 7-day intrathecal injection of combinatory drugs could signifi-
cantly increase the pain threshold in cold and mechanical allodynia at 
15 min after injection, and this effect remained till 60 min postinjec-
tion. Evaluation of mechanical hyperalgesia confirmed the obtained 
results.
Some studies confirm that GABA receptors are found in areas 
of the nervous system that are essential for pain relief. Due to the 
large dispersion of GABAergic neurons in the brain and spinal cord, 
the stimulation of these neurons can have different effects, includ-
ing analgesia or hyperalgesia. It is believed that the stimulation of 
GABA A receptors in the spinal cord leads to analgesia, whereas 
GABA A receptors stimulation in areas higher than the spinal cord 
can	cause	hyperalgesia	(Enna	&	McCarson,	2006).	Coincident	with	
this hypothesis, our study showed that the stimulation of GABA A 
receptors in the spinal cord decreased the pain threshold.
At the time of injury occurrence, the body is able to release sub-
stances such as endogenous endorphins that have an analgesic effect 
and suppress the pain message before reaching higher levels in the 
nervous system. Endomorphins are secreted from peptidergic neu-
rons. Their receptors are dose-dependent (the decrease and increase 
in receptors depends on the dose used) and, unlike external morphine, 
endomorphins can be easily decomposed in the body. Endomorphins-1 
and 2 can be extracted and isolated from the human brain and the cow 
(Przewłocki	et	al.,	1999).	Some	researchers	have	also	shown	that	en-
domorphins concentration and the analgesic effect of them decrease 
after	SCI	(Chen	&	Pan,	2006;	Wolfe	et	al.,	2007).
In	this	study,	SCI	did	not	change	the	NMDA	receptor's	NR1	sub-
unit expression compared with the control group, and it was also 
observed that the combination therapy significantly increased the 
expression level of this subunit in comparison with the control and 
SCI group. Moreover, seven-day administration of endomorphin-1 





expression	 24	 hr	 postlesion	 (Brown,	 Wrathall,	 Yasuda,	 &	 Wolfe,	
2004).	These	 results	are	similar	 to	 the	 results	of	our	experiments.	
Other studies found that nerve damage increased the amount 
of	NR2B	subunit	expression,	with	no	 impact	on	 the	expression	of	
the	NR2A	 subunit	 and	 relative	decline	of	NR1	 subunit	 expression	
(Wilson	et	al.,	2005).	The	severe	sensitivity	of	NMDA	receptors	fol-
lowing neuronal damage is acceptable to the majority of research-
ers.	In	a	study	that	NMDA	receptor's	NR1	subunit	was	removed	in	
the	 spinal	 cord	 neurons,	 it	was	 observed	 that	 in	 rats	 lacking	NR1	
gene,	not	only	NMDA	receptor	activity	was	blocked	but	also	symp-
toms such as severe mechanical and thermal sensitivities erupted. 
Neurons	 lacking	NR1	subunit	showed	features	such	as	 increase	of	
irritability and activity of excitatory synapses due to increased fre-
quency of action potentials in the spinal cord (Pagadala et al., 2013).
All of these findings point to the fact that following neuronal 
damage, and all subsequent cycles, from progression to recovery, 
NMDA	 receptors,	 are	 highly	 dynamic	 (Caudle,	 Perez,	 Del	 Valle-
Pinero,	&	Iadarola,	2005).	Although	many	studies	have	already	been	
done	on	 the	 role	and	 importance	of	 the	NR2	subunit	 in	 the	activ-
ity	of	NMDA	receptors,	the	role	of	the	NR1	subunit	 is	still	unclear.	
Henderson,	Pittman,	&	Teskey	(2012)	concluded	that	following	the	
induction of high-frequency stimuli into the neocortex region, en-
hancement	in	the	GABA	A	receptor's	α2 subunit expression and the 
NR1	subunit	of	the	NMDA	receptor	would	occur.	It	was	also	stated	
that	this	increase	would	occur	in	the	expression	of	the	NR1	subunit	
in each receptor, and in other words, the number of these subunits 




2004).	 It	 has	 been	 proven	 that	 oxidative	 stress	 contributes	 to	 the	
development	of	diseases	such	as	neuropathic	pain,	Alzheimer's	and	
Parkinson's	disease	(Xu	et	al.,	2008).	Since	the	reactive	oxygen	spe-
cies (ROS) activity in the spinal cord and changes in the antioxidant 
system are important causes of pain and hyperalgesia (Wilson et al., 
2005), in this study, the effects of microinjection of muscimol and 
endomorphin-1 on the antioxidant system were investigated. Briefly, 
increased ROS in spinal cord may induce pain by reducing GABA in-
hibitory influence on spinal dorsal horn neurons that are involved in 
pain transmission. Therefore, using antioxidants can alter the balance 
to improve symptoms of pain or using a GABA agonist can fix the 
defect caused by ROS.
Malondialdehyde is a toxic molecule and is considered as an in-
dicator	 of	 oxidative	 stress	 that	 interferes	 with	 DNA	 and	 proteins	
and results in leukemia and cellular degradation. MDA level is used 
as an indicator of lipid peroxidation, which indicates the amount 
of	damage	caused	by	free	oxygen	radicals	(Kerimoğlu	et	al.,	2007).	
In the present study, MDA level was significantly increased in the 
SCI and Vehicle groups compared to the control group. Meanwhile, 
the level of this substance in the group receiving muscimol and en-
domorphin-1 was significantly lower than the SCI group. On the 
other hand, there was no significant difference between the group 
receiving the combination of drugs and control group. This finding 
revealed the protective effect of combination therapy on MDA pro-
duction. Our results indicated a significant decrease in SOD activity 
of SCI and Vehicle group compared with the control group. As noted, 
combination therapy could efficiently improve SOD activity nearly 
to control and sham group. However, there was no significant differ-
ence between the group receiving the medication individually (mus-
cimol and endomorphin) with the group receiving the combination of 
drugs. This suggests the effectiveness of prescribing a combination 
of drugs to bring the SOD level back to the normal range.
Our results showed that GSH activity was significantly de-
creased in the SCI group as compared with the control group. In SCI 
group that received combination therapy, GSH activity efficiently 
improved nearly to control group and was significantly higher than 
the SCI group.
Some studies have shown that hippocampal neurons with overex-
pression of SOD exhibit a higher level of inhibitory and spontaneous 
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synaptic currents. These inhibitory currents inhibit membrane de-
polarization.	The	physiological	mechanism	of	this	 inhibition	is	due	to	
the upregulation of GABA-dependent neurotransmission. It has been 
seen that SOD can directly affect GABA-dependent neurotransmitter 
transmissions	(Levkovitz,	Avignone,	Groner,	&	Segal,	1999).
Treatment with muscimol and endomorphin-1 in combination 
and individually markedly increased GSH and SOD activity when 
compared with the SCI group.
On the other hand, in all figures of oxidative stress, there was 
no significant difference between the group receiving the drug 
combination and the normal group. This demonstrates the effi-
cacy of combination drug administration to return MDA, SOD, and 
GSH levels to normal levels. Therefore, it can be concluded that 
combination of the drugs is maybe more effective than individual 
injection of them to cure all the aspects of spinal cord injury such 
as oxidative stress.
5  | CONCLUSION
Overall, the results of this study indicate that combination ther-
apy with muscimol and endomorphin-1 for seven consecutive days 
can reduce the pain threshold of animals with SCI compared to 
the administration of each medication individually. Isobologram 
studies indicated that the interaction of muscimol and endo-
morphin-1 is additive. It was also found that simultaneous use of 
muscimol and endomorphin could improve the reduction in the 
expression of 2α subunit expression of GABA A receptors after 
spinal cord injury to normal. Simultaneous use of muscimol and 
endomorphin-1	 also	 increases	 the	 amount	of	NR1	 subunit	 from	
NMDA	receptors.
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